
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are approximately 50 such guidances planned.
FDA has issued a list of planned draft and final guidance documents for release throughout 2012. There are about 50 such
In biopharmaceutics and biosimilarity:
In combination products:
In CGMPs and compliance:
In labeling, packaging, and supply chain:
In regulatory filings (electronic):





